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Unidad de Alergia, Asma e Inmunolog ıa Clinica, Capital Federal, Argentina, 2 Unidad de Alergia, Asma e Inunologia Clinica, CABA, Argentina, 3 Unidad de Alergia, Asma e Inmunologia Clinica, CABA, Argentina. RATIONALE: The best treatment for common variable immunodeficiency (CVID) patients with granulomatous disease remains elusive. METHODS: We describe the follow up of a CVID patient with infliximab responsive granulomatous disease. RESULTS: We have previously described a now 72 year old white woman diagnosed as CVID at the age of 41. Serum IgG was 112 mg%, IgA 7 mg% and IgM 31 mg%. She was placed on monthly IVIG with good infectious control. From 1999 she developed necrotizing granulomatous nodular lesions affecting her vocal cords, conjunctiva and skin. Some of her skin lesions became ulcerated and painful. She initially improved on high dose prednisone but had severe steroid adverse effects including several vertebral fractures. Cutaneous lesions extended to all limbs, became ulcerated and severely painful. Ciclosporin up to 5 mg/Kg failed to control. In 2008, infliximab 5 mg/Kg was initiated and, after four courses, all but one ulcer were resolved. For the next 11 years, she had immediate skin flares as soon as infliximab was stopped. In 2017 she had an ITP, stopped infliximab and received high dose steroids. When steroids were tapered painful skin ulcers reappeared that were controlled again with infliximab. Laboratory studies showed an increase in IgM levels after placed on infliximab that kept variable high until infliximab was stopped; high circulating CD4+ follicular helper T cells and CD20+ B cells diminishing over time to 1%. CONCLUSIONS: Long term follow-up of this infliximab responsive CVID patient shows an unremitting course of this complication and an unexplained relationship between serum IgM with infliximab. (PPV23) is an integral part of the evaluation and diagnosis of humoral antibody deficiencies. Although there are guidelines on how to interpret overall vaccine responses, there is a paucity of evidence on the significance of individual serotypes as possible predictors of immunodeficiency or future risk of immunodeficiency. METHODS: We performed a statistical evaluation of age, serum immunoglobulins, and pre-and post-vaccination pneumococcal titers of individuals with recurrent infections to predict their response, nonresponse, or transient response. An ordinal method was used to determine statistical significance. Four hundred ninety-two patients were screened, and three hundred patients met the inclusion criteria. RESULTS: If a pre-vaccine titer to serotype 8 is between 0.65 and 1.05 mg/mL and serotype 5 is less than 0.6 mg/mL the patient will most likely respond to the vaccine (responder). If a pre-vaccine titer to serotype 8 is greater than 1.05 mg/mL and the serum IgG is less than 597.5 mg/dL the patient will most likely not respond to the vaccine (non-responder). If the serotype 8 is less than 0.65 mg/mL, serotype 3 is less than 0.25 mg/mL, age is less than 34.5 years, and the IgA is between 64 and 124 mg/dL they will most likely be a transient responder (transient). CONCLUSIONS: The predictability of initial immunological testing to determine progression has not been fully elucidated. We show that an evaluation of age, immunoglobulin levels, and pre-vaccination serotype titers can suggest a response to PPV-23 in a responder, non-responder, and transient responder.
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Optimization and clinical application of lymphocyte proliferation test using 5-bromo-29-deoxyuridine for the allergic patients Norio Kawamoto, MD, PhD, Minako Kawamoto, MD PhD, and Toshiyuki Fukao, MD, PhD; Department of Pediatrics, Graduate School of Medicine, Gifu University, Gifu City, Japan. RATIONALE: The lymphocyte proliferation test (LPT) has been used to diagnose allergic diseases such as food protein-induced enterocolitis syndrome (FPIES) or drug allergy. For most LPTs, the radioisotopetritiated thymidine (3HTdR) is commonly used owing to its higher sensitivity and wider dynamic range. An alternative cell proliferation assay is LPT using 5-bromo-2'-deoxyuridine (BrdU), which is a nonradioactive analog of 3HTdR. We optimized the LPT protocol using BrdU and performed this test for patients with allergies. METHODS: Peripheral blood mononuclear cells (PBMCs) were obtained from healthy individuals or patients with allergies after written informed consent, and an allergic response was stimulated with either an allergen or phytohemagglutinin (PHA) as a positive control. Stimulated samples were labeled with 10 mmol/L of BrdU in the final 2 hours or overnight and analyzed with a chemiluminescent-based BrdU ELISA kit. The stimulation index (SI) was calculated as the ratio of stimulated-to-unstimulated chemiluminescence intensity. RESULTS: The overnight BrdU labeling showed higher signal intensity than the 2-hour BrdU labeling. The time course study for the incubation period of 3-6 days showed that days 5 and 6 were higher in allergen stimulation. Proliferation of PBMCs from patients with FPIES following antigen stimulation with milk, alpha casein, beta casein, kappa casein, and beta-lactoglobulin was observed using BrdU, which was consistent with that observed using 3HTdR. CONCLUSIONS: LPT using BrdU may be applicable for the clinical diagnoses of allergic diseases. Additionally, the optimal stimulant dose and cutoff value need to be determined.
